About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
Drug Shortages (4-Part Series)
In the first article in this four-part series, Dr. Babinchak discusses the scope and consequences of antimicrobial shortages.
Timothy J. Babinchak, MD
New treatments for gram-positive and gram-negative bacteria, rheumatoid arthritis, and migraine, along with a new antiviral drug for the treatment of HIV-1 infection.
Marvin M. Goldenberg, PhD
Continuing Education Credit
The author provides an overview of anticonvulsants approved during the past 25 years for the treatment and
management of seizures.
Gale M. Tucker, PharmD, RPh
David B. Nash, MD, MBA, Editor-in-Chief,
goes beyond bar codes to “FindtheDOT.”
David B. Nash, MD, MBA
The latest information about approvals, indication changes, industry updates, and news from the FDA.
Stephen Barlas discusses the forthcoming
pharmaceutical “Rules of Engagement.”
Review of Almotriptan: A 5-HT1B/1D agonist for the treatment of migraine.
Brooke D. Fidler, PharmD
Matthew Grissinger, RPh, discusses the question
of who is to blame for “omission errors.”
Matthew Grissinger, RPh